Código QR (código de barras bidimensional)

The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma

Abstract Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer. In this study, we analyze the role of muscle loss in patie...

ver descrição completa

Na minha lista:
Principais autores: Michael Praktiknjo, Ana S. Pena Solano, Farsaneh Sadeghlar, Thomas Welchowski, Matthias Schmid, Christian Möhring, Taotao Zhou, Robert Mahn, Malte B. Monin, Carsten Meyer, Georg Feldmann, Peter Brossart, Cornelius van Beekum, Alexander Semaan, Hanno Matthaei, Steffen Manekeller, Alois M. Sprinkart, Sebastian Nowak, Julian Luetkens, Jörg C. Kalff, Christian P. Strassburg, Maria A. González-Carmona
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Portfolio 2024-09-01
coleção:Scientific Reports
Acesso em linha:https://doi.org/10.1038/s41598-024-66766-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados